Interval CRC as lethal as clinically-detected CRC – 3 study insights

A study published in Gastroenterology examined individuals with interval colorectal cancer who underwent sigmoidoscopy screening to patients with clinically-detected CRC who had not been screened.

Researchers performed a secondary analysis Norway-based randomized sigmoidoscopy screening data. About 20,552 underwent screenings, while 78,126 did not undergo sigmoidoscopy screening. Researchers compared 163 patients with CRC mortality and all-cause mortality who were screened then diagnosed with CRC to a group of 1,740 unscreened patients diagnosed with CRC .

Here's what you should know:

1. Forty-three individuals in the screened interval cancer group died from CRC. About 525 in the control group died from CRC.

2. Rectosigmoid cancer mortality and all-cause mortality did not differ between the screened interval cancer group and the controls.

3. Researchers concluded, "In this randomized sigmoidoscopy screening trial, mortality did not differ significantly between individuals with interval CRCs and unscreened patients with clinically detected CRCs."

More articles on gastroenterology:
Beaumont Health opening 2 outpatient campuses with surgery centers — 6 insights
4 things to know about Regent Surgical Health's CEO Chris Bishop
3 strategies for ASC accounts receivable management

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers